Maladie de Parkinson Vers un mécanisme de mort neuronale

Agid, 1998, Adverse reactions to levodopa: drug toxlcity or progression of disease?, Lancet, 351, 851, 10.1016/S0140-6736(05)70285-3 Alam, 1997, Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra, J. Neurochem., 69, 1196, 10.1046/j.1471-4159.1997.69031196.x Ambiani, 1975, Brain peroxidase and catalase in Parkinson's disease, Arch. Neurol., 32, 114, 10.1001/archneur.1975.00490440064010 Anglade, 1997, Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease, Histol. Histopathol., 12, 25 Bachurin, 1991, Pyridine derivatives: structure-activity relationships causing parkinsonism-like symptoms, Rev. Environ. Contam. Toxicol., 122, 1, 10.1007/978-1-4612-3198-1_1 Banati, 1998, Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease, Mov. Disord., 13, 221, 10.1002/mds.870130205 Basu, 1998, BAD enables ceramide to signal apoptosis via Ras and Raf-1, J. Biol. Chem., 273, 30419, 10.1074/jbc.273.46.30419 Beckman, 1990, Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and Superoxide, 87, 1620 Bindorff, 1991, Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease, J. Neurol. Sci., 104, 203, 10.1016/0022-510X(91)90311-T Blin, 1994, Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy, J. Neurol. Sci., 125, 95, 10.1016/0022-510X(94)90248-8 Boka, 1994, Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease, Neurosci. Lett., 172, 151, 10.1016/0304-3940(94)90684-X Bradford, 1999, Neurotrophins in the pathcgenesis and potential treatment of Parkinson's disease, Adv. Neurol., 80, 19 Brassat, 1999, Génétique de la maladie de Parkinson, Rev. Méd. Interne, 20, 709, 10.1016/S0248-8663(99)80493-7 Brookes, 1994, Synuclein proteins and Alzheimer's disease, Trends Neurosci., 17, 404, 10.1016/0166-2236(94)90013-2 Brugg, 1996, Ceramide induces apoptosis in cultured mesencephalic neurons, J. Neurochem., 66, 733, 10.1046/j.1471-4159.1996.66020733.x Calne, 1992, The free radical hypothesis in Parkinson's disease: evidence against it, Ann. Neurol., 32, 799, 10.1002/ana.410320615 Caparros-Lefebvre, 1999, Carribean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study, Lancet, 354, 281, 10.1016/S0140-6736(98)10166-6 Cardellach, 1993, Mitochondrial respiratory chain activilY in skeletal muscle from patients with Parkinson's disease, Neurology, 4, 2258, 10.1212/WNL.43.11.2258 Checkoway, 1999, Epidemiologic approaches to the study of Parkinson's disease etiology, Epidemiology, 10, 327, 10.1097/00001648-199905000-00023 Chen, 1995, MPP+ selectively affects calcium homeostasis in mesencephalic cell cultures from embryonal C57/B16 mice, J. Neuronal. Transm. Gen. Sect., 100, 153, 10.1007/BF01271538 Clarke, 1990, Developmental cell death: morphological diversity and mutltiple mechanisms, Anat. Embryol., 181, 195, 10.1007/BF00174615 Cleeter, 1992, Irreversible inhibition of mitochondrial complex I by 1-methyl-4-pyridinium: evidence for free radical involvement, J. Neurochem., 58, 786, 10.1111/j.1471-4159.1992.tb09789.x Connor, 1994, Isoforms of ferritin have a specific cellular distribution in the brain, J. Neurosci. Res., 37, 461, 10.1002/jnr.490370405 Connor, 1995, A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's disease brains, J. Neurochem., 65, 717, 10.1046/j.1471-4159.1995.65020717.x Conway, 1998, Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease, Nat. Med., 4, 1318, 10.1038/3311 Cosi, 1996, Poly (ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57/B1/6 mice, Brain Res., 729, 264 Damier, 1993, Glutathione peroxidase, glial cells and Parkinson's disease, Neuroscience, 52, 1, 10.1016/0306-4522(93)90175-F Damier, 1999, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease, Brain, 122, 1437, 10.1093/brain/122.8.1437 Darios, 1999, Different cell death mechanisms associated with increased cytosolic or mitochondrial free calcium: ultrastructural study, Abstract Soc. Neurosci., 25, 1523 Datta, 1997, Akt phosphorylation of BAD couples survial signals to the cell-intrinsic death machinery, Cell, 91, 231, 10.1016/S0092-8674(00)80405-5 Desagher, 1996, Astrocytes protect neurons from hydrogen peroxide toxicity, J. Neurosci., 16, 2553, 10.1523/JNEUROSCI.16-08-02553.1996 Di Monte, 1999, Impaired glutamate clearance as a consequence of energy failure caused by MPP (+) in astrocytic cultures, Toxicol. Appl. Pharmacol., 58, 296, 10.1006/taap.1999.8717 Duan, 1999, Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease, Ann. Neurol., 46, 587, 10.1002/1531-8249(199910)46:4<587::AID-ANA6>3.0.CO;2-M Dziewczapolski, 1997, Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats, Neuroreport, 8, 975, 10.1097/00001756-199703030-00031 Earle, 1968, Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue, J. Neuropathol. Exp. Neurol., 27, 1, 10.1097/00005072-196801000-00001 Elbaz, 1999, Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. Europarkinson Study Group, Neurology, 52, 1876, 10.1212/WNL.52.9.1876 Fahn, 1992, The oxidant stress hypothesis in Parkinson's disease: evidence supporting it, Ann. Neurol., 32, 804, 10.1002/ana.410320616 Farrer, 1999, A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor, Hum. Mol. Genet., 8, 81, 10.1093/hmg/8.1.81 Faucheux, 1995, Expression of lactoferritin receptors is increased in the mesencephalon of patients with Parkinson's disease, 92, 9603 Faucheux, 1997, The density of [125I]-ferrotransferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease, Brain Res., 749, 170, 10.1016/S0006-8993(96)01412-6 Faucheux, 1999, Blood vessels change in the mesencephalon of patients with Parkinson's disease, Lancet, 353, 981, 10.1016/S0140-6736(99)00641-8 France-Lanord, 1997, Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease, J. Neurochem., 69, 1612, 10.1046/j.1471-4159.1997.69041612.x Garcia-Ruiz, 1997, Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione, J. Boil. Chem., 272, 11369, 10.1074/jbc.272.17.11369 Gasser, 1998, A susceptibility locus for Parkinson's disease maps to chromosome 2pl3, Nature Genet., 18, 1, 10.1038/ng0398-262 Ghafourifar, 1999, Ceramide induces cytochrome C release from isolated mitochodria: importance of mitochondrial redox state, J. Biol. Chem., 274, 6080, 10.1074/jbc.274.10.6080 Good, 1998, Protein nitration in Parkinson's disease, J. Neuropathol. Exp. Neurol., 57, 338, 10.1097/00005072-199804000-00006 Gorell, 1999, Occupational metal exposures and the risk of Parkinson's disease, Neuroepidemiology, 18, 303, 10.1159/000026225 Graham, 1978, Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol. Pharmacol., 14, 633 Grilli, 1999, Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction, Biochem. Pharmacol., 57, 1, 10.1016/S0006-2952(98)00214-7 Grimm, 1996, Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis, J. Cell. Biol., 134, 13, 10.1083/jcb.134.1.13 Grondin R., Gash D.M., Glial cell-line derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease, J. Neurol. 245 (Suppl. 3) 35–42. Gu, 1998, Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease, Ann. Neurol., 44, 177, 10.1002/ana.410440207 Gudz, 1997, Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide, J. Biol. Chem., 272, 23154, 10.1074/jbc.272.39.24154 Gulbins, 1995, FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway, Immunity, 2, 341, 10.1016/1074-7613(95)90142-6 Hanna, 1999, Genetics and molecular pathogenesis of mitochondrial respiratory chain diseases, Cell Mol. Life Sci., 55, 691, 10.1007/s000180050327 Hartfield, 1998, Neurotrophic factors prevent ceramide-induced apoptosis downstream of c-Jun N-terminal kinase activation in PC12 cells, J. Neurochem., 71, 161, 10.1046/j.1471-4159.1998.71010161.x Hida, 1999, Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes, J. Neurosci., 19, 7458, 10.1523/JNEUROSCI.19-17-07458.1999 Hirsch, 1993, Does oxidative stress participate in nerve cell death in Parkinson's disease?, Eur. Neurol., 33, 52, 10.1159/000118538 Hirsch, 1999, Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease, vol. 80 Hirsch, 1998, Iron metabolism and Parkinson's disease, Mov. Disord., 13, 39 Hulley, 1995, Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo, Eur. J. Neurol., 7, 2431 Hunot, 1996, Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease, J. Neural. Transm., 103, 1043, 10.1007/BF01291789 Hunot, 1996, Nitric oxide synthase and neuronal vulnerability in Parkinson's disease, Neuroscience, 72, 355, 10.1016/0306-4522(95)00578-1 Hunot, 1997, Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease, Proa Natl. Acad. Sci. USA, 94, 7531, 10.1073/pnas.94.14.7531 Hunot, 1999, FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells, J. Neurosci., 19, 3440, 10.1523/JNEUROSCI.19-09-03440.1999 Jellinger, 1999, Post mortem studies in Parkinson's disease —is it possible to detect brain areas for specific symptoms, J. Neural. Transm., 1, 10.1007/978-3-7091-6360-3_1 Jenner, 1998, Levodopa neurotoxicity: experimental studies versus clinical relevance, Neurology, 50, S39, 10.1212/WNL.50.6_Suppl_6.S39 Jenner, 1992, Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group, Ann. Neurol., 32, S82, 10.1002/ana.410320714 Kaltschmidt, 1993, Potential involvement of the transcription factor NF-kappa B in neurological disorders, Mol. Aspects Med., 14, 171, 10.1016/0098-2997(93)90004-W Kang, 1998, Activation of c-jun N-terminal kinase/stress-activated protein kinase and the decreased ratio of Bcl-2 to Box are associated with the auto-oxidized dopamine-induced apoptosis in PC12 cells, Neurosci. Lett., 256, 37, 10.1016/S0304-3940(98)00751-4 Kingsbury, 1998, DNA fragmentation in human substantia nigra: apoptosis or perimortem effect?, Mov. Disord., 13, 877, 10.1002/mds.870130604 Kinscherf, 1998, Apoptosis caused by oxidized LDL is manganese Superoxide dismutase and p53 dependent, FASEB J., 12, 461, 10.1096/fasebj.12.6.461 Kisby, 1992, Cycasin and BMAA: candidate neurotoxins for Western Pacific amyotrophic lateral sclerosis/parkinsondementia complex, Neurodegeneration, 1, 73 Kitada, 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, 605, 10.1038/33416 Kolesnick, 1998, Regulation of ceramide production and apoptosis, Annu. Rev. Physiol., 60, 643, 10.1146/annurev.physiol.60.1.643 Kosel, 1997, On the question of apoptosis in the parkinsonian substantia nigra, Acta Neuropathol. (Berl), 93, 105, 10.1007/s004010050590 Krige, 1992, Platelet mitochondrial function in Parkinson's disease, Ann. Neurol., 32, 782, 10.1002/ana.410320612 Kroemer, 1998, The mitochondrial death/life regulator in apoptosis and necrosis, Annu. Rev. Physiol., 60, 619, 10.1146/annurev.physiol.60.1.619 Kruger, 1998, Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease, Nature Genet., 8, 106, 10.1038/ng0298-106 Kruman, 1997, Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis, J. Neurosci., 17, 5089, 10.1523/JNEUROSCI.17-13-05089.1997 Lambeng, 1999, Mechanisms of apoptosis in PC12 cells irreversibly differentiated with nerve growth factor and cyclic AMP, Brain Res., 821, 60, 10.1016/S0006-8993(99)01061-6 Langston, 1996, The etiology of Parkinson's disease with emphasis on the MPTP story, Neurology, 47, S153, 10.1212/WNL.47.6_Suppl_3.153S Lannuzel, 1999, Extracts from Annona Muricata (soursop) are toxic to dopaminergic neurons: potential role in the etiology of atypical parkinsonism in the French West Indies, Abstracts Soc. Neurosci., 25, 2018 Le Couteux, 1999, Pesticides and Parkinson's disease, Biomed. Pharmacother., 53, 122, 10.1016/S0753-3322(99)80077-8 Leist, 1998, 1-methyl-4-phenylpyridinium induces autocrine excitotoxidty, protease activation, and neuronal apoptosis, Mol. Pharmacol., 54, 789, 10.1124/mol.54.5.789 Leroy, 1998, The ubiquitin pathway in Parkinson's disease, Nature, 395, 451, 10.1038/26652 Lezoualc'h, 1998, Transcription factor NF-kappaB: friend or foe of neurons?, Mol. Psychiatry, 3, 15, 10.1038/sj.mp.4000295 Li, 1998, J. Neurochem., 71, 2049, 10.1046/j.1471-4159.1998.71052049.x Lightowlers, 1999, Mitochondrial DNA —all things bad?, Trends Genet., 15, 91, 10.1016/S0168-9525(98)01684-9 Marini, 1989, The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells, J. Neurosci., 9, 3665, 10.1523/JNEUROSCI.09-10-03665.1989 Marks, 1999, Recent advances on neuronal caspases in development and neurodegeneration, Neurochem. Int., 35, 195, 10.1016/S0197-0186(99)00061-3 Marshall, 1997, Upregulation of the antiapoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease, Biochem. Biophys. Res. Commun., 240, 84, 10.1006/bbrc.1997.7604 Mathias, 1991, Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor alpha, 88, 10009 Mattson, 1997, Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration, J. Neurosci. Res., 49, 681, 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3 McGeer, 1988, Expression of the histocompatibility glycoprotein HLA-DR in neurological disease, Acta Neuropathol. (Berl), 76, 550, 10.1007/BF00689592 McLaughlin, 1998, Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor, J. Neurochem., 70, 2406, 10.1046/j.1471-4159.1998.70062406.x McNaught, 1998, Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease, Biochem. Pharmacol., 56, 921, 10.1016/S0006-2952(98)00142-7 Mezey, 1998, Alpha synuclein in neurodegenerative disorders: murderer or accomplice?, Nat. Med., 4, 755, 10.1038/nm0798-755 Michel, 1990, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture, J. Neurosci. Res., 26, 428, 10.1002/jnr.490260405 Michel, 1992, Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains, J. Neurochem., 59, 118, 10.1111/j.1471-4159.1992.tb08882.x Michel, 1997, Rescue of mesencephalic dopamine neurons by anticancer drug cytosine arabinoside, J. Neurochem., 69, 1499, 10.1046/j.1471-4159.1997.69041499.x Michel, 1999, Neuropharmacologic aspects of apoptosis: significance for neurodegenerative diseases, Clin. Neuropharmacol., 22, 137 Michel, 1999, Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes, J. Neurochem., 72, 2074, 10.1046/j.1471-4159.1999.0722074.x Mochizuki, 1996, Histochemical detection of apoptosis in Parkinson's disease, J. Neurol. Sci., 137, 120, 10.1016/0022-510X(95)00336-Z Mogi, 1996, The soluble form of Fas molecule is elevated in parkinsonian brain tissues, Neurosci. Lett., 220, 195, 10.1016/S0304-3940(96)13257-2 Mogi, 1996, Bcl-2 protein is increased in the brain from parkinsonian patients, Neurosci. Lett., 215, 137, 10.1016/0304-3940(96)12961-X Mori, 1998, Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q, Neurology, 51, 890, 10.1212/WNL.51.3.890 Morrett, 1999, A novel transactivation domain in parkin, Trends in Biochem. Sci., 24, 229, 10.1016/S0968-0004(99)01381-X Muller, 1998, Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling, EMBO J., 17, 732, 10.1093/emboj/17.3.732 Nagatawa-Hattori, 1992, Parkinson's disease a mitochondrial disorder, J. Neurol. Sci., 107, 29, 10.1016/0022-510X(92)90205-Y Naoi, 1998, (R) Salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes, Ann. Neurol., 43, 212, 10.1002/ana.410430211 Nicotera, 1999, Excitotoxins in neuronal apoptosis and necrosis, J. Cereb. Blood Flow Metab., 19, 583, 10.1097/00004647-199906000-00001 Nicotera, 1999, Execution of apoptosis: converging or diverging pathways, Biol. Chem., 380, 1035, 10.1515/BC.1999.129 Ochu, 1998, Involvement of caspases in C2-ceramide-induced apoptosis in PC12 cells, J. Neurochem., 70, 2637, 10.1046/j.1471-4159.1998.70062637.x Offen, 1999, Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis, Adv. Neurol., 80, 265 Oh, 1995, Overexpression of Bcl-2 attenuates MPP+; but not 6-OHDA, induced cell death in a dopaminergic neuronal cell line, Neurobiol. Dis., 2, 157, 10.1006/nbdi.1995.0017 Ostrerova, 1999, α-synuclein shares physical and functional homology with 14-3-3 proteins, J. Neurosci., 19, 5782, 10.1523/JNEUROSCI.19-14-05782.1999 Oyanagi, 1999, Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update, J. Neurol., 246, S19, 10.1007/BF03161078 Pahan, 1999, Induction of the manganese superoxide dismutse gene by sphingomyelinase and ceramide, J. Neurochem., 73, 513, 10.1046/j.1471-4159.1999.0730513.x Pahwa, 1999, Progressive supranuclear palsy, Med. Clin. North Am., 83, 369, 10.1016/S0025-7125(05)70109-7 Pandolfo, 1999, Molecular pathogenesis of Friedreich ataxia, Arch. Neurol., 56, 1201, 10.1001/archneur.56.10.1201 Parain, 1999, Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra, Neuroreport, 10, 557, 10.1097/00001756-199902250-00021 Parker, 1989, Abnormalities of the electron transport chain in idiopathic Parkinson's disease, Ann. Neurol., 26, 719, 10.1002/ana.410260606 Pfeilschifter, 1998, Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells, Kidney Int., S34, 10.1046/j.1523-1755.1998.06707.x Polymeropoulos, 1998, Mutation in the alpha synuclein gene identified in families with Parkinson's disease, Lancet, 351, 2045 Przedborski, 1998, Mechanisms of MPTP toxicity, Mov. Disord., 13, 35 Przedborski, 1996, Role of neuronal nitric oxide in 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) -induoced dopaminergic neurotoxicity, 93, 4565 Qureshi, 1995, Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease, Neuroreport, 6, 1642, 10.1097/00001756-199508000-00013 Radi, 1994, Inhibition of mitochondrial electron transport by peroxynitrite, Arch. Biochem. Biophys., 308, 89, 10.1006/abbi.1994.1013 Radunovic, 1997, Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex, Neurosci. Lett., 239, 105, 10.1016/S0304-3940(97)00905-1 Reif, 1990, Nitric oxide mediates iron release from ferritin, Arch. Biochem. Biophys., 283, 537, 10.1016/0003-9861(90)90680-W Ruberg, 1997, Is differential regulation of mitochondrial transcripts in Parkinson's disease related to apoptosis?, J. Neurochem., 68, 2098, 10.1046/j.1471-4159.1997.68052098.x Ruberg, 1998, Parkinson's disease, apoptosis and oxidative stress Saporito, 1999, CEP-1347/KT-7515 an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo, J. Pharmacol. Exp. Ther., 288, 421 Savitz, 1998, Apoptosis in neurological disease, Neurosurgery, 42, 555, 10.1097/00006123-199803000-00026 Schapira, 1995, Nuclear and mitochondrial genetics in Parkinson's disease, J. Mol. Genet., 32, 411 Schapira, 1989, Mitochondrial complex I deficiency in Parkinson's disease, Lancet, 1, 1269, 10.1016/S0140-6736(89)92366-0 Schipper, 1999, Mitochondrial iron sequestration in dopamine-challenged astioglia: role of heme oxygenase-1 and the permeability transition pore, J. Neurochem., 72, 1802, 10.1046/j.1471-4159.1999.0721802.x Schoffner J.N., Watts R., Juncos J.L., Torroni A., Wallace D.C., Mitochondrial defects in basal ganglia diseases, Curr. Opin. Neurol. 32 (Suppl.) S116-S124. Schulz, 1995, Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice, J. Neurochem., 64, 936, 10.1046/j.1471-4159.1995.64020936.x Seaton, 1998, Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins, Brain Res., 809, 12, 10.1016/S0006-8993(98)00790-2 Selley, 1998, (E) -4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkin-son's disease, Free Radic. Biol. Med., 25, 169, 10.1016/S0891-5849(98)00021-5 Shimoda-Masubayashi, 1997, MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control, Neurology, 49, 1257, 10.1212/WNL.49.5.1257 Shimura, 1999, Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients, Ann. Neurol., 45, 668, 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z Sonsalla, 1998, Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism, Amino Acids, 14, 69, 10.1007/BF01345245 Spacey, 1999, The genetics of Parkinson's disease, Curr. Opin. Neurol., 12, 427, 10.1097/00019052-199908000-00009 Spencer, 1998, Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species, J. Neurochem., 71, 2112, 10.1046/j.1471-4159.1998.71052112.x Spillantini, 1998, α-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Stout, 1998, Glutamate-induced neuron death requires mitochondrial calcium uptake, Nat. Neurosci., 1, 366, 10.1038/1577 Susin, 1997, The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/Apo-1/CD95-and ceramide-induced apoptosis, J. Exp. Med., 186, 25, 10.1084/jem.186.1.25 Swerdlow, 1996, Origin and functional consequences of the complex I defect in Parkinson's disease, Ann. Neurol., 40, 663, 10.1002/ana.410400417 Swerdlow, 1998, Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family, Ann. Neurol., 44, 873, 10.1002/ana.410440605 Takeda, 1999, Ceramide generation in nitric oxide-induced apoptosis, J. Biol. Chem., 274, 10654, 10.1074/jbc.274.15.10654 Thompkins, 1997, Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigra neurons, Am. J. Pathol., 150, 119 Tortosa, 1997, Bcl-2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and diffuse Lewy body disease, Neurosci. Lett., 238, 78, 10.1016/S0304-3940(97)00837-9 Tsacopoulos, 1996, Metabolic coupling between glia and neurons, J. Neurosci., 16, 877, 10.1523/JNEUROSCI.16-03-00877.1996 Tsai, 1998, Nitric oxide donors protect cultured rat astrocytes irom 1-methyl-4-phenylpyridinium-induced toxicity, Free Radic. Biol. Med., 24, 705, 10.1016/S0891-5849(97)00329-8 Ueda, 1993, Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease, 90, 11282 Vernadakis, 1988, Neuron-glia interelations, Int. Rev. Neurobiol., 50, 149, 10.1016/S0074-7742(08)60049-5 Vieregge, 1992, Life-style and dietary factors in early and late Parkinson's disease, Can. J. Neurol. Sci., 19, 170, 10.1017/S0317167100042219 Vila, 1997, Consequences of nigrstriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybrization study of cytochrome oxidase subunit 1 mRNA, J. Neurosci., 17, 765, 10.1523/JNEUROSCI.17-02-00765.1997 Vyas, 1997, Expression of Bcl-2 in adult human brain regions with special reference to neurodegenerative disorders, J. Neurochem., 69, 223, 10.1046/j.1471-4159.1997.69010223.x Wallach, 1999, Tumor necrosis factor receptor and Fas signaling mechanisms, Annu. Rev. Immunol., 17, 331, 10.1146/annurev.immunol.17.1.331 Watton, 1999, Akt/PKB localisation and 3′ phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction, Curr. Biol., 9, 433, 10.1016/S0960-9822(99)80192-4 Wiederholt, 1999, Neuroepidemiologic research initiatives on Guam: past and present, Neuroepidemiology, 18, 279, 10.1159/000026223 Yang, 1995, Bad a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, Cell, 80, 285, 10.1016/0092-8674(95)90411-5 Yao, 1995, Phosphorylation of Raf by ceramide activated protein kinase, Nature, 378, 307, 10.1038/378307a0 Yoritaka, 1996, Imunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, 93, 2696 Yoshida, 1994, Cerebrospinal fluid levels of superoxide dismutses in neurological diseases detected by sensitive enzyme immunoassays, J. Neurol. Sci., 124, 25, 10.1016/0022-510X(94)90006-X Zhang, 1996, Bcl-2 interrupts the ceramide-mediated pathway of cell death, 93, 5323 Zhou, 1998, Inhibition of Akt kinase by cellpermeable ceramide and its implications for cermide-induced apoptosis, J. Biol. Chem., 273, 16568, 10.1074/jbc.273.26.16568 Zipp, 1998, CD95 (Apo-1/Fas) and Parkinson's disease, Ann. Neurol., 44, 426, 10.1002/ana.410440331